CELL INTELLIGENCE · 肿瘤细胞治疗研究

NK 细胞免疫治疗儿童实体瘤的生产成本分析与探索性经济评估

Manufacturing cost analysis and exploratory economic evaluation of natural killer cell immunotherapy for paediatric solid tumors.

NK 细胞疗法显示出指示性的早期经济信号，值得进一步的临床和经济研究。微观成本核算识别出可操作的制造成本驱动因素，为工艺优化提供信息，这些探索性估计为随着临床证据发展而进行的迭代经济评估奠定了基础。

儿童实体瘤的生物工程细胞疗法：未满足需求与测量整合方法

Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.

儿童实体瘤的嵌合抗原受体（CAR）-T 细胞疗法：当前突破、困境与策略

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.

免疫功能低下宿主中耐药革兰阴性感染的新型抗生素：从关键试验到高风险实践

Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice.

儿童实体瘤的过继性细胞治疗

Adoptive Cell Therapy for Pediatric Solid Tumors.

2024 EBMT 活动报告：跨越 100 万例造血细胞移植和 20, 000 例 CAR-T，细胞治疗领域的里程碑

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

载体 MSC 的内在免疫特性影响接受溶瘤病毒治疗的儿童实体瘤患者的临床结局

Intrinsic immune properties of carrier MSC impact on the clinical outcome of children with solid tumors receiving oncolytic virotherapy.

CAR-T 细胞治疗临床试验全景与发展趋势的全球多维分析

A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.

CAR-T 细胞治疗在儿童、青少年和年轻成人癌症患者中的关键作用

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

肿瘤微环境中的 B7-H3：对儿童实体瘤 CAR-T 细胞治疗的意义

B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors.